![](/img/cover-not-exists.png)
Optimal treatment strategy with nilotinib for patients with newly diagnosed chronic-phase chronic myeloid leukemia based on early achievement of deep molecular response (MR 4.5 ): The phase 2, multicenter N-Road study
Nishiwaki, Kaichi, Sugimoto, Kei-ji, Tamaki, Shigehisa, Hisatake, Junichi, Yokoyama, Hisayuki, Igarashi, Tadahiko, Shinagawa, Atsushi, Sugawara, Takeaki, Hara, Satoru, Fujikawa, Kazuhisa, Shimizu, SeiJournal:
Cancer Medicine
DOI:
10.1002/cam4.3034
Date:
April, 2020
File:
PDF, 561 KB
2020